Clinical Trial Update: Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating apatinib combined with chemotherapy in non-small cell lung cancer patients without EGFR T790M mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN